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Abstract
We present here a case of immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma
(KS-IRIS) developed in an AIDS patient two months after initiation of antiretroviral therapy (ART). Baseline characteristics
of this IRIS-KS case, within a cohort of 12 naïve AIDS-KS patients, were analyzed. No statistically significant differences in
CD4 cell counts, plasma HIV RNA load, KS clinical staging, human herpesvirus 8 (HHV8) antibody titers and HHV8 load
in peripheral blood mononuclear cells and saliva were evidenced. HHV8 load in plasma was found to be significantly
higher in the KS-IRIS patient (> 6 log10 genome equivalents/ml, p = 0.01, t–test) compared to the 11 patients with KS
regression. This case highlights that measurement of HHV8 load in plasma may be useful to identify patients at risk for
KS-IRIS, and that this parameter should be included in the design of larger studies to define KS-IRIS risk predictors.
Keywords: Immune reconstitution inflammatory syndrome, IRIS, Kaposi’s sarcoma, KS, KS-IRIS, HHV8, KSHV, Biomarker
Introduction
Although it was initially reported in HIV-negative pa-
tients, the immune reconstitution inflammatory syn-
drome (IRIS) occurs more frequently in HIV-infected
patients initiating antiretroviral therapy (ART). IRIS re-
sults from restored immunity causing an exaggerated
inflammatory response against persistent infectious or
non-infectious antigens [1–5] and occurs with a wide
spectrum of clinical manifestations. IRIS may cause wors-
ening of previously treated infections, tumor progression
in patients with proliferative disorders, or unmasking of
subclinical infections, with tumor development in patients
co-infected with an oncogenic virus. One of the parame-
ters predictive of IRIS is severe CD4 cell lymphopenia
prior to ART initiation (< 50 cells/μl). Other relevant bio-
markers are the elevated antigenic burden of an oppor-
tunistic infection and a decrease of at least more than 1
log10 HIV RNA in plasma, which represents one of the
major criteria for the definition of IRIS [1, 2, 5].
A subset of patients (6–20 %) co-infected with human
herpesvirus 8 (HHV8) may develop Kaposi’s sarcoma
(“unmasking” Kaposi’s sarcoma-associated IRIS, KS-
IRIS) or experience acute worsening of pre-existing
tumor (“paradoxical” KS-IRIS) within a short interval
(2–3 months) after ART initiation. The clinical course
of KS-IRIS varies greatly according to the analyzed
population, as demonstrated by Letang et al. [6] in a
pooled analysis of 436 AIDS-KS patients initiating ART
from two distinct geographical areas, UK and sub-
Saharan Africa. KS-IRIS can be self-limiting in well-
resourced countries, with a tendency to regress even
without therapy readjustment. On the other hand, this
condition is frequently associated with high mortality
in sub-Saharan countries, reflecting the more advanced
stage at presentation and the higher frequencies of co-
morbidities and coinfections in African populations.
The study by Letang et al. [6] identified the following
baseline biomarkers for risk stratification: ART alone as
initial KS treatment, T1 KS clinical stage, and high
plasma HIV RNA load (> 5 log10 copies/ml). Moreover,
detectable baseline plasma HHV8 DNA was also found
to predict KS-IRIS development in a subset of 259
patients, whereas quantification of plasma viral load
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showed no significant differences. However, the IRIS con-
dition is characterized by an immunological disturbance
in untreated AIDS-KS patients, leading to systemic activa-
tion of HHV8 lytic replication with subsequent viremia.
Thus, baseline systemic viral burden might be useful
for risk stratification, as previously demonstrated in
IRIS associated with opportunistic infections and in
AIDS-KS patients, in which a better clinical response
was found to be correlated to a baseline plasma HHV8
load below 660 copies/ml [7].
Case report
A 39-year-old HIV-positive homosexual male was admit-
ted to our Infectious Diseases Unit with asthenia and
multiple (11) painless, nodular purple lesions concen-
trated in the trunk that ranged from 0.5 to 2.0 cm in the
largest dimension. The patient was diagnosed with HIV
infection and cutaneous Kaposi’s sarcoma was confirmed
by histological examination. Either mucocutaneous and
visceral involvement was excluded by endoscopic and
neck, chest and abdominal computerized tomography
(CT) examinations. The CD4 lymphocyte count was 360
cells/μl (14 %) and plasma HIV-1 RNA level was 4.09
log10 copies/ml. Parameters linked to HHV8 infection
status, evaluated as previously reported [8–10], revealed
active lytic replication, with high burden of cell-free
viral progeny in plasma [6.16 log10 genome equivalents
(GE)/ml] and saliva (4.95 log10 GE/ml, Table 1). The
patient started a combined ART (cART) with daruna-
vir/ritonavir plus coformulated tenofovir/emtricitabine.
Four weeks after cART initiation, examination of the
patient revealed stable cutaneous KS lesions; the CD4
lymphocyte count had increased to 810 cells/μl (20 %)
and the plasma HIV RNA was undetectable (< log10 40
copies/ml). Within a further 4 week-treatment, the pa-
tient showed recrudescent KS, with an increased num-
ber of lesions (> 20 cutaneous lesions) and enlargement
of pre-existing ones. CD4 cell count was 820 cells/ml
(21 %) and HIV RNA viral load was under the limit of
detectability. The sudden clinical KS worsening to-
gether with the rapid immunovirological response was
indicative of an immune reconstitution inflammatory
syndrome rather than KS progression. The patient con-
tinued the antiretroviral combination therapy and no
systemic KS chemotherapy was administrated. KS-IRIS
flare completely recovered in 10 months.
To test the usefulness of previously reported KS-IRIS
predictors [6], we analyzed baseline characteristics of the
preceding 11 consecutive cART-naïve AIDS-KS patients
referring to the Infectious Diseases Units of Padova and
Rovigo, and followed at the Veneto Institute of Oncology
for HHV8 diagnostics. All 11 patients had histologically
confirmed KS. They had initiated combined antiretroviral
therapy (cART) showing immunovirological response,
accompanied by KS regression (data not shown), during
the first 3 months of follow-up. Baseline characteristics of
all KS patients are reported in Table 1. In the KS group,
data are expressed as median and interquartile range
(25th–75th percentile) calculated on the measurable sam-
ples. To compare the values of different biomarkers of the
KS-IRIS case to those of the KS group, the one-tailed
Crawford and Howell t-test was used [11]. No statistically
significant differences in CD4 cell counts, plasma HIV
RNA load, KS clinical staging [12], HHV8 antibody titers
and HHV8 load in PBMC were observed. Conversely,
HHV8 load in plasma was measurable in 11 of 12 patients,
and was found to be significantly higher in the KS-IRIS
case (> 6 log10 GE/ml, p = 0.01) compared to those mea-
sured in patients with KS regression. Moreover, HHV8
load in saliva was higher, albeit not statistically significant
(p = 0.09), in the KS-IRIS case (Table 1).
Table 1 Characteristics of the 12 male KS patients at study entry
KS-IRIS (N= 1) KS (N = 11)a
Demographics Median (IQR)
Age (years) 39 35 (31.5–53)
Risk factor N









HIV- and HHV8-related parameters Median (IQR)
CD4 cell count (cells/μl) 360 190 (80–335)
HIV plasma load (log10 copies/ml) 4.09 4.97 (3.89–5.31)
HHV8 PBMC load (GE/105 cells) 76 100 (26.50–160.75)
HHV8 plasma load (log10 GE/ml) 6.16
b 3.48 (3.26–3.76)
HHV8 saliva load (log10 GE/10
5 cells) 4.95 2.87 (1.84–4.14)
HHV8 ORF65 antibodiesc < 50 400 (100–800)
HHV8 LANA antibodiesc 12,800 800 (250–4,800)
KS-IRIS Kaposi’s sarcoma-associated immune reconstitution inflammatory
syndrome, KS Kaposi’s sarcoma, IQR interquartile range, HHV8 human herpesvirus
8, PBMC peripheral blood mononuclear cells, GE genome equivalents, ORF65 open
reading frame 65, encoding for a structural protein expressed during the
lytic phase, LANA latency-associated nuclear antigen. aIn the KS group, data
are expressed as median (interquartile range) calculated on the measurable
samples. bSignificantly higher in the KS-IRIS case vs. KS group (p = 0.01). To
perform statistical analysis, samples in which HIV RNA (N = 2) could not be
detected were assigned an arbitrary value of log1040, specimens in which
HHV8 ORF65 antibodies (N = 3) were not detected an arbitrary value of 40,
and those in which HHV8 GE were not detected (PBMC, N = 3; plasma, N = 1;
saliva, N = 1) were assigned an arbitrary value of 5 (PBMC) or log105.
cAntibody
titers were determined using 1:50 as first dilution, and are expressed as reciprocal
of the highest dilution giving a positive result
Cattelan et al. Infectious Agents and Cancer  (2016) 11:5 Page 2 of 4
Discussion
These findings, although limited to a small cohort, indi-
cate that plasma HHV8 DNA detectability may not be
so informative, and are fully in line with previously
published studies. Indeed, 78.4 % of ART-naïve AIDS-
KS patients from Zimbabwe had measurable plasma
load, with a baseline median value of 2.82 log10 copies/
ml [6, 7]. Moreover, HHV8 viremia was detectable at
study entry in more than 90 % of AIDS-KS patients be-
longing to the Chelsea and Westminster HIV cohort,
one of the largest cohorts in Europe, with a baseline
median HHV8 load ranging from 4.6 to 5 log10 copies/
ml [13]. The same cohort was analyzed in the pooled
analysis [6], and plasma HHV8 DNA detectability, de-
termined only in 104 patients, dropped to 58.3 % in this
selected population, as did the baseline median value
(2.87 log10 copies/ml) of plasma HHV8 load. We think
that these discrepancies might be due to different sensi-
tivities in the quantitative techniques, if samples were
independently reanalyzed, or to a unrecognized bias re-
lated to the selection of the 104 patients for the pooled
analysis. Another population of AIDS-KS patients in-
cluded in Letang et al. [6] is the Durban cohort, from
South Africa [14]; about half of these samples (54/112)
were analyzed in the pooled analysis, and 74.1 % of the
samples have measurable plasma HHV8 load, with a base-
line median value of 2.24 log10 copies/ml [6]. Therefore,
most of the individual studies showed high frequencies of
HHV8 detectability in plasma, as did our small cohort;
these figures are far from the highest, measured or esti-
mated, incidences of KS-IRIS in any analyzed population,
indicating that the HHV8 detection per se cannot be a
predictive parameter.
Conclusion
This case highlights that, in our small cohort, the measure-
ment of baseline HHV8 load in plasma was useful to iden-
tify the patient who experienced a KS-IRIS. Therefore, we
recommend including quantification of baseline parame-
ters linked to HHV8 infection status, specifically measure-
ment of HHV8 load in plasma and, possibly, in saliva, in
the design of larger studies to define KS-IRIS predictors.
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